These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2027475)

  • 1. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Cedarbaum JM; Gandy SE; McDowell FH
    Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
    Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Kostic V; Przedborski S; Flaster E; Sternic N
    Neurology; 1991 Feb; 41(2 ( Pt 1)):202-5. PubMed ID: 1992362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor complications associated with chronic levodopa therapy in Parkinson's disease.
    Obeso JA; Grandas F; Vaamonde J; Luquin MR; Artieda J; Lera G; Rodriguez ME; Martinez-Lage JM
    Neurology; 1989 Nov; 39(11 Suppl 2):11-9. PubMed ID: 2685647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
    Kostić VS; Marinković J; Svetel M; Stefanova E; Przedborski S
    Eur J Neurol; 2002 Jan; 9(1):9-14. PubMed ID: 11784369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor complications in an incident Parkinson's disease cohort.
    Scott NW; Macleod AD; Counsell CE
    Eur J Neurol; 2016 Feb; 23(2):304-12. PubMed ID: 26074125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
    Schrag A; Quinn N
    Brain; 2000 Nov; 123 ( Pt 11)():2297-305. PubMed ID: 11050029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring.
    van Hilten JJ; Kabel JF; Middelkoop HA; Kramer CG; Kerkhof GA; Roos RA
    Acta Neurol Scand; 1993 Mar; 87(3):171-7. PubMed ID: 8475685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with motor complications in Parkinson's disease.
    Kadastik-Eerme L; Taba N; Asser T; Taba P
    Brain Behav; 2017 Oct; 7(10):e00837. PubMed ID: 29075578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.